Natalie Sacks will resign from her position as chief medical officer of Aduro Biotech (NASDAQ: [[ticker:ADRO]]) effective Oct. 1, the cancer immunotherapy developer announced Wednesday. Berkeley, CA-based Aduro gave no reason for the resignation, but said that Sacks will continue to advise the company through a consulting agreement. Sacks joined Aduro in 2016. Last year, the company wound down work on the drug CRS-207 after disappointing results in mesothelioma, ovarian, and gastric cancer studies. The company has since turned its focus to three other early-stage programs for a number of cancers.
